Table 1 Participant characteristics.

From: A preliminary study of the physiological and perceptual effects of GLP-1 receptor agonists during alcohol consumption in people with obesity

 

Overall

Control

GLP-1RA

p

n

20

10

10

 

Age (mean (SD))

36.35 (9.85)

34.90 (11.26)

37.80 (8.56)

0.525

Education (mean (SD))

16.25 (2.94)

16.00 (3.74)

16.50 (2.01)

0.714

Employment (%)

 Full time

14 (70.0)

5 (50.0)

9 (90.0)

0.173

 Part time

2 (10.0)

2 (20.0)

0 (0.0)

 Unemployed

4 (20.0)

3 (30.0)

1 (10.0)

Ethnicity = Not Hispanic or Latino (%)

19 (95.0)

9 (90.0)

10 (100.0)

> 0.999

Sex = M (%)

4 (20.0)

3 (30.0)

1 (10.0)

0.582

Race = White (%)

20 (100.0)

10 (100.0)

10 (100.0)

 

AUDIT_C (mean (SD))

3.55 (1.50)

3.60 (1.71)

3.50 (1.35)

0.886

AUDIT (mean(SD))

4.65 (3.12)

5.10 (3.07)

4.20 (3.26)

0.533

TLFB - Days (mean(SD))

7.00 (7.00)*

9.86 (9.01)*

4.50 (3.63)*

0.145

TLFB - Drinks/day

0.44 (0.38)

0.60 (0.49)

0.30 (0.21)

0.133

BMI (mean (SD))

38.60 (5.33)

37.98 (4.57)

39.21 (6.18)

0.619

HbA1c (mean (SD))

5.22 (0.30)

5.28 (0.32)

5.16 (0.29)

0.389

Medication (%)

 Liraglutide

2 (20.0)

 

2 (20.0)

 

 Semaglutide

6 (60.0)

 

6 (60.0)

 

 Tirzepatide

2 (20.0)

 

2 (20.0)

 

Days on maintenance dose (mean (SD))

76.30 (55.07)

 

76.30 (55.07)

 
  1. Demographic and medication information of our sample. We observed no differences in these variables between the control and GLP-1RA groups. * a hardware problem resulted in some data loss.
Back to article page